Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · IEX Real-Time Price · USD
3.090
-0.130 (-4.04%)
At close: Jul 19, 2024, 4:30 PM
3.080
-0.010 (-0.32%)
Pre-market: Jul 20, 2024, 9:28 AM EDT
Sagimet Biosciences Revenue
Sagimet Biosciences had revenue of $2.00M in the twelve months ending March 31, 2024. In the year 2023, Sagimet Biosciences had annual revenue of $2.00M.
Revenue (ttm)
$2.00M
Revenue Growth
n/a
P/S Ratio
49.31
Revenue / Employee
$200,000
Employees
10
Market Cap
98.61M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.00M | - | - |
Dec 31, 2022 | 0 | - | - |
Dec 31, 2021 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSGMT News
- 5 weeks ago - Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat - GlobeNewsWire
- 6 weeks ago - Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024 - GlobeNewsWire
- 2 months ago - Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024 - GlobeNewsWire
- 2 months ago - Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 2 months ago - Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024 - GlobeNewsWire
- 2 months ago - Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer - GlobeNewsWire
- 3 months ago - Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024 - GlobeNewsWire
- 4 months ago - Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat - GlobeNewsWire